By Ben Butkus

Upstart molecular diagnostics firm PathoGene said yesterday that it has raised $750,000 in seed money, exceeding its original goal of $500,000, to fund clinical evaluation of its PCR-based molecular assays for difficult-to-treat and drug-resistant infectious diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.